RT Conference Proceedings
T1 BAFF, APRIL Y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY?
A1 Prieto-Pena, D.
A1 Genre, F.
A1 Martinez, S. Remuzgo
A1 Pulito-Cueto, V.
A1 Atienza-Mateo, B.
A1 Sevilla, B.
A1 Llorca, J.
A1 Ortego, N.
A1 Leonardo, M.
A1 Penalba, A.
A1 Martin-Penagos, L.
A1 Fillloy, J. A. Miranda
A1 Narvaez, J.
A1 Montero, L. Caminal
A1 Collado, P.
A1 Fernandez-Nebro, A.
A1 Diaz-Cordoves, G.
A1 Cigarran, S.
A1 Calvino, J.
A1 Cobelo, C.
A1 De-Argila, D.
A1 Vicente-Rabaneda, E. F.
A1 Rubio-Romero, E.
A1 Luque, M. Leon
A1 Blanco-Madrigal, J. M.
A1 Galindez-Agirregoikoa, E.
A1 Gualillo, O.
A1 Ibanez, J. Martin
A1 Castaneda, S.
A1 Blanco, R.
A1 Gonzalez-Gay, M. A.
A1 Lopez-Mejias, R.
K1 B-Lymphocytes
K1 Cells
K1 Glomerulonephritis, IGA
K1 Cytokines
AB Background: IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions [1, 2], that share pathogenic mechanisms [1], in which B-lymphocytes are described as key cells implicated in these processes. BAFF, APRIL, and BAFF-R are cytokines implicated in the development of B-lymphocytes [3, 4] and in autoimmune processes [5, 6]. In this regard, an influence of BAFF, APRIL, and BAFFR polymorphisms was observed on several immune-mediated conditions, with BAFF GCTGT>A being a shared insertion-deletion variant for inflammatory conditions [7, 8]. Objectives: To determine whether BAFF, APRIL, and BAFFR could be used as differential biomarkers between IgAV and IgAN. Methods: BAFF rs374039502 (which colocalizes with BAFF GCTGT>A), two tag variants within APRIL (rs11552708 and rs6608), and two tag variants within BAFFR (rs7290134 and rs77874543) were genotyped in 394 Caucasian IgAV patients, 95 patients with IgAN, and 832 matched healthy controls.
PB BMJ Group
SN 0003-4967
YR 2022
FD 2022-06-01
LK http://hdl.handle.net/10668/20051
UL http://hdl.handle.net/10668/20051
LA en
NO Prieto-Peña, D., Genre, F., Martinez, S. R., Pulito-Cueto, V., Atienza-Mateo, B., Sevilla, B., et al. AB0146 BAFF, APRIL y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY? Annals Of The Rheumatic Diseases, 81(Suppl 1), 1203-1204. https://doi.org/10.1136/annrheumdis-2022-eular.425
NO This study was supported by the European Regional Development Fund (ERDF) and “Fondo de Investigaciones Sanitarias” (grant PI18/00042 and PI21/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, 'Investing in your future') [grant number CM20/00006]; SR-M is supported by funds of the RETICS Program co-funded by ERDF [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; RL-M is a recipient of a Miguel Servet type II programme fellowship from the ISCIII, co-funded by ESF 'Investing in your future' [grant number CPII21/00004].
DS RISalud
RD Apr 10, 2025